Business Context and Reporting Period
Pavmed Inc., a Delaware corporation and emerging growth company, filed this Form 8-K on January 19, 2018. The filing reports the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 2,415,278 firm shares plus an option to purchase up to 362,292 additional shares.
- Public Offering Price: $1.80 per share.
- Underwriter Discount: $0.144 per share (8% of the public offering price).
- Expected Net Proceeds: Approximately $3.9 million (firm shares only) or $4.5 million (if the over-allotment option is exercised in full).
- Underwriter: Dawson James Securities, Inc. (sole underwriter).
- Expected Closing Date: On or about January 23, 2018.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity. The transaction is being made pursuant to a shelf Registration Statement on Form S-3 declared effective on October 6, 2017.
Outlook, Risks, and Management Commentary
Management has priced the offering and signed the underwriting agreement. The offering is subject to customary closing conditions. The filing includes standard representations and warranties but does not provide specific forward-looking guidance on future operations or financial performance beyond the expected proceeds from this transaction.
Key Facts for Investor Verification
- Verify the final closing date and whether the over-allotment option was exercised to confirm total proceeds.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification obligations.
- Confirm the use of proceeds as detailed in the accompanying prospectus supplement.
- Check subsequent filings for the actual number of shares issued and final net proceeds received.